Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyra Therapeutics, Inc. (Nasdaq: LYRA) SEC filings page on Stock Titan provides access to the company’s public reports and current reports filed with the U.S. Securities and Exchange Commission. Lyra identifies itself in these filings as a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS), with its common stock listed on The Nasdaq Capital Market under the symbol LYRA.
Through Lyra’s Forms 10-K and 10-Q, readers can review detailed financial statements, including collaboration revenue, research and development expenses related to the ENLIGHTEN Phase 3 clinical program for LYR-210, general and administrative costs, restructuring charges, and cash and cash equivalents balances. These periodic reports also describe the company’s status as a clinical-stage entity with no approved products and discuss risks such as ongoing losses, funding needs, and dependence on clinical trial outcomes.
Current reports on Form 8-K document material events that are important for understanding LYRA’s situation. Examples include notices from The Nasdaq Stock Market regarding compliance with listing requirements, such as minimum bid price and stockholders’ equity thresholds; details of a registered direct offering and concurrent private placement of warrants; and changes in board and executive roles. Other 8-K filings reference the posting of corporate presentations that discuss LYR-210 and the ENLIGHTEN clinical program.
For those interested in clinical and strategic developments, Lyra’s filings and attached exhibits often cross-reference press releases that summarize ENLIGHTEN 2 Phase 3 results, pooled analyses in patients with nasal polyps, and regulatory interactions with the U.S. Food and Drug Administration. More recent corporate updates, including the decision by Lyra’s Board of Directors to suspend further development of LYR-210 and cease product development operations, are reflected in company disclosures and provide important context for interpreting financial and risk disclosures.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered tools can help readers quickly identify key sections in lengthy reports, such as risk factors, management’s discussion and analysis, restructuring notes, and disclosures related to Nasdaq listing status, financing agreements, and strategic alternatives under consideration.
Lyra Therapeutics insider amendment corrects previously reported stock-option activity and clarifies current holdings. The reporting person, Maria Palasis, was originally granted performance stock options totaling 11,000 shares (stated as 550,000 pre-split) on
Maria Palasis, President & CEO and a director of Lyra Therapeutics, Inc. (LYRA), reported a change in beneficial ownership after the company determined on 10/01/2025 that Milestone 2 under a performance stock option (PSO) award was achieved. The PSO grant, originally made on 03/21/2024, covered up to 11,000 shares; 3,667 PSOs were earned as a result of Milestone 2. Those earned PSOs are exercisable under the award terms and will vest on 01/31/2028. Following the reported transaction, the filing shows 7,333 shares of common stock beneficially owned directly by the reporting person. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Palasis and dated 10/03/2025.
Lyra Therapeutics, Inc. filed a report noting that on September 4, 2025 it posted a new corporate presentation on its website. Company representatives may use this presentation in discussions with investors, analysts, and other interested parties.
The presentation is provided as Exhibit 99.1 to the report and is incorporated by reference, giving stakeholders a centralized source for updated company information. Lyra’s common stock trades on the Nasdaq Capital Market under the symbol LYRA.
Lyra Therapeutics reported receipt of a Nasdaq deficiency letter because its stockholders' equity was approximately $1.6 million as of June 30, 2025, below the Nasdaq Capital Market minimum requirement of $2.5 million. The filing states the deficiency letter has no immediate effect on the listing or trading of the company's common stock, which will continue to trade on Nasdaq under the symbol LYRA. The company points investors to its Annual Report and Quarterly Report for risk disclosures and reiterates standard forward-looking statements caution. The report is dated August 22, 2025, and signed by CFO Jason Cavalier.
Perceptive Advisors and related parties report a 15.55% beneficial stake in Lyra Therapeutics. The Schedule 13D/A discloses ownership of 255,750 shares of Lyra common stock out of 1,644,454 shares outstanding as reported in the filing. Ownership is held collectively by Perceptive Advisors LLC and affiliated entities: Perceptive Life Sciences Master Fund, Ltd. (229,982 shares, 13.99%) and Perceptive LS (A), LLC (25,768 shares, 1.57%). The cover pages show shared voting and dispositive power over the reported shares and identify the source(s) of funds as stated in the filing. The filing provides a clear ownership breakdown and the percentage calculations based on the issuer's reported outstanding shares.
Lyra Therapeutics reported mixed clinical and financial results for the quarter. The company announced positive Phase 3 ENLIGHTEN 2 results for LYR-210, showing statistically significant improvement versus sham in the three-cardinal-symptom composite (3CS) at 24 weeks in patients without nasal polyps (treatment effect -1.13; p=0.0078), in the full population (-0.90; p=0.0209), and in SNOT-22 score (-8.7; p=0.0101). LYR-210 was generally well tolerated with no product-related serious adverse events.
On the financial side, Lyra had $29.8 million in cash and cash equivalents at June 30, 2025 and an accumulated deficit of approximately $420.8 million. Net loss was $7.4 million for the quarter and $16.0 million for the six months ended June 30, 2025. The company completed a June 2025 financing that raised $5.0 million gross ($4.3 million net) and sold shares under its shelf registration generating $26.7 million of proceeds (net). Following an earlier failed Phase 3 ENLIGHTEN 1 trial and related cost reductions (including a workforce reduction of 87 employees and impairment charges), management disclosed substantial doubt about its ability to continue as a going concern and has paused commercialization and certain development and manufacturing activities while pursuing strategic and cost-saving actions.
Lyra Therapeutics filed an 8-K reporting it announced financial results for the quarter ended June 30, 2025. The filing states the company furnished a press release as Exhibit 99.1 and posted a corporate presentation on its website, furnished as Exhibit 99.2. Both exhibits are expressly described as "furnished, and not filed," and the company disclaims any obligation to update the presentation. The filing identifies Lyra's common stock as trading under the symbol LYRA on The Nasdaq Capital Market and indicates the company is an emerging growth company. The report is signed by CFO Jason Cavalier on August 12, 2025.